1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study.
Saved in:
| Title: | 1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study. |
|---|---|
| Authors: | Weichenthal, M.1 (AUTHOR), Gavrilova, I.2 (AUTHOR), Mangana, J.3 (AUTHOR), Leiter-Stoppke, U.4 (AUTHOR), Ellebaek, E.5 (AUTHOR), Ruhlmann, C.H.6 (AUTHOR), Ugurel-Becker, S.7 (AUTHOR), Asher, N.8 (AUTHOR), Kandolf Sekulovic, L.9 (AUTHOR), Gerasimov, A.10 (AUTHOR), Dummer, R.11 (AUTHOR), Ziogas, D.C.12 (AUTHOR), Haanen, J.B.A.G.13 (AUTHOR), Svane, I.M.5 (AUTHOR), Espinosa, E.14 (AUTHOR), Rutkowski, P.15 (AUTHOR), Mohr, P.16 (AUTHOR), Gogas, H.12 (AUTHOR), Bastholt, L.6 (AUTHOR), Schadendorf, D.17 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS963-S964. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2251 |
